Valeant Pharmaceuticals International (NYSE:VRX) reported 3/31/2018 earnings this Morning, coming in at $0.89 per share, beating Wall Street’s estimates of $0.60 per Share. Revenue for the quarter came in at $2.00 billion beating analyst estimates of $1.95 billion Recent Insider Trading for Valeant Pharmaceuticals International (NYSE:VRX)
- On 3/13/2018 Joseph C Papa, CEO, bought 30,000 with an average share price of $16.05 per share and the total transaction amounting to $481,500.00.
- On 3/13/2018 Paul Herendeen, CFO, bought 15,000 with an average share price of $16.10 per share and the total transaction amounting to $241,500.00.
- On 3/8/2018 Schutter Richard U De, Director, bought 10,000 with an average share price of $15.34 per share and the total transaction amounting to $153,400.00.
- On 3/6/2018 John Paulson, Director, bought 7,066,629 with an average share price of $15.40 per share and the total transaction amounting to $108,826,086.60.
- On 11/16/2017 John Paulson, Director, bought 344,216 with an average share price of $14.40 per share and the total transaction amounting to $4,956,710.40.
- On 8/21/2017 Schutter Richard U De, Director, bought 10,000 with an average share price of $14.33 per share and the total transaction amounting to $143,300.00.
Dividend History for Valeant Pharmaceuticals International (NYSE:VRX)
Recent Trading for Valeant Pharmaceuticals International (NYSE:VRX) Shares of Valeant Pharmaceuticals International closed the previous trading session at 20.15 up +1.99 10.96% with 19.600000381469727 shares trading hands.